Fortis-Manipal Hospitals Enterprises Deal To Create India's Largest Healthcare Service Provider
Fortis Healthcare Ltd said on Tuesday it would sell its hospital business to Manipal Hospitals Enterprises Private Ltd, creating the largest provider of healthcare services in India by revenue.
For every 100 shares of Fortis held, a shareholder will receive 10.83 shares in Manipal Hospitals, the combined company that will be created following the deal, Fortis said.
Fortis, based in Gurugram, also said it approved the sale of a 20 per cent stake in diagnostics chain SRL Ltd to Manipal Hospitals, providing Fortis with more than Rs 700 crore.
Manipal Hospitals will be a publicly-traded company listed on the National Stock Exchange and the Bombay Stock Exchange, while remaining businesses with Fortis Healthcare will be an investment holding company with 36.6 per cent stake in SRL, Fortis said.
Dr Ranjan Pai and US-based private equity firm TPG Capital, a shareholder in Manipal Hospitals since 2015, will invest Rs 3,900 crore in Manipal Hospitals, to finance the acquisition of 50.9 per cent stake in SRL.
Manipal Hospitals is in discussions to buy 30.9 per cent held by other investors in the diagnostics chain.
The investment will also support the proposed acquisition of hospital assets owned by RHT Health Trust and the growth of the hospitals and the diagnostics businesses, Fortis said.
Fortis' main backers, Malvinder Singh and Shivinder Singh, resigned from its board last month following legal troubles related to the sale of their stake in Ranbaxy to Japan's Daiichi Sankyo Co Ltd. The Ranbaxy case is unrelated to Fortis.
"We continue to support the management and the board to successfully transition to the new joint entity," the Singh brothers said in a statement late Tuesday.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets